

Electronic Supplementary Material

Manuscript Title: Safety Profile of GSK's Inactivated Quadrivalent Seasonal Influenza Vaccine in Belgium, Germany and Spain: Passive Enhanced Safety Surveillance Study for the 2019/2020 Influenza Season

Journal: Drug Safety

Authors: Ignacio Salamanca de la Cueva¹ Elisa Cinconze² Tamara Eckermann³ Ugo Nwoji⁴ Lode Godderis^{5,6} Emily Lu⁴ Xavier Martínez-Gómez⁷ Huajun Wang⁸ Emad Yanni⁴

Affiliations:

¹ Instituto Hispalense de Pediatría, Sevilla, Spain

² GSK, Siena, Italy

³ Hausarztpraxis Heimeranplatz, Munich, Germany

⁴ GSK, Rockville, MD, USA

⁵ Environment and Health, Department of Public Health and Primary Care, KU Leuven, Louvain, Belgium

⁶ IDEWE, External Service for Prevention and Protection at Work, Heverlee, Belgium

⁷ Hospital Universitari Vall d'Hebron, Barcelona, Spain

⁸ GSK, Amsterdam, The Netherlands

Corresponding Author:

Emad Yanni

Mailing address: GSK, Rockville, MD, USA

Phone: +1 215 751 3088

Email address: emad.a.yanni@gsk.com

Table S1 Weekly percentages of participants reporting any AEs within 7 days post vaccination from week 40 of 2019 to week 01 in 2020 (Safety Set)

ISO week	Weekly, after dose 1			Weekly, after dose 2		
	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)
40	65	13	20.0 (0.0–97.6)			
41	150	55	36.7 (1.2–91.9)			
42	169	79	46.8 (16.5–79.0)			
43	34	11	32.4 (8.2–66.7)			
44	67	35	52.2 (0.0–100)			
45	163	61	37.4 (21.2–56.0)			
46	251	96	38.3 (30.1–46.9)			
47	143	60	42.0 (20.7–65.7)			
48	30	11	36.7 (16.5–61.0)	4	1	25.0 (0.6–80.6)
49	10	3	30.0 (0.0–100)	20	3	15.0 (3.2–37.9)
50				22	2	9.1 (1.1–29.2)
51				30	0	0.0 (0.0–11.6)
52				25	3	12.0 (2.6–31.2)
01*				14	0	0.0 (0.0–23.2)

AE, adverse event; CI, confidence interval (extended Clopper–Pearson exact CI for clustered data); ISO, International Organization for Standardization; LL, lower limit; *N*, number of participants vaccinated with GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4) in the specified ISO weeks; *n*, number of participants vaccinated with GSK's IIV4 in the specified ISO weeks reporting at least one AE; UL, upper limit; % = (*n*/*N*) x 100

* first ISO week of 2020

Table S2 Number of AEs reported within 7 days post vaccination per participant (Safety Set)

Number of AEs per participant	After dose 1 <i>N</i> = 1,082		After dose 2 <i>N</i> = 115	
	<i>n</i>	%	<i>n</i>	%
0	658	60.8	106	92.2
1	167	15.4	4	3.5
2	96	8.9	1	0.9
3	77	7.1	2	1.7
4	43	4.0	2	1.7
5	21	1.9	0	0.0
6	5	0.5	0	0.0
7	10	0.9	0	0.0
8	1	0.1	0	0.0
9	1	0.1	0	0.0
10	2	0.2	0	0.0
11	0	0.0	0	0.0
12	1	0.1	0	0.0
mean	0.9		0.2	

AE, adverse event; *N*, total number of participants; *n*, %, number and percentage of participants reporting the specific number of AEs

Table S3 Cumulative percentages of participants reporting any AEs within 7 days post vaccination with dose 1 (Safety Set)

ISO week	Belgium			Germany			Spain			Total		
	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)
40–40	0			65	13	20.0 (0.0–97.6)	0			65	13	20.0 (0.0–97.6)
40–41	0			215	68	31.6 (1.6–84.5)	0			215	68	31.6 (1.6–84.5)
40–42	113	61	54.0 (44.4–63.4)	271	86	31.7 (2.1–82.6)	0			384	147	38.3 (13.2–69.1)
40–43	131	68	51.9 (41.5–62.2)	287	90	31.4 (2.8–79.1)	0			418	158	37.8 (17.6–61.7)
40–44	142	77	54.2 (11.3–92.7)	287	90	31.4 (2.8–79.1)	56	26	46.4 (33.0–60.3)	485	193	39.8 (23.6–57.8)
40–45	220	109	49.6 (24.7–74.6)	287	90	31.4 (2.8–79.1)	141	55	39.0 (30.9–47.6)	648	254	39.2 (27.4–52.0)
40–46	285	134	47.0 (18.1–77.5)	287	90	31.4 (2.8–79.1)	327	126	38.5 (13.2–69.6)	899	350	38.9 (30.5–47.9)
40–47	317	144	45.4 (15.0–78.7)	287	90	31.4 (2.8–79.1)	438	176	40.2 (4.7–86.7)	1042	410	39.4 (31.6–47.5)
40–48	328	149	45.4 (15.8–77.8)	287	90	31.4 (2.8–79.1)	457	182	39.8 (6.3–83.1)	1072	421	39.3 (31.9–47.1)
40–49	330	149	45.2 (15.0–78.2)	287	90	31.4 (2.8–79.1)	465	185	39.8 (6.5–82.8)	1082	424	39.2 (31.8–47.0)
40–50	330	149	45.2 (15.0–78.2)	287	90	31.4 (2.8–79.1)	465	185	39.8 (6.5–82.8)	1082	424	39.2 (31.8–47.0)
40–51	330	149	45.2 (15.0–78.2)	287	90	31.4 (2.8–79.1)	465	185	39.8 (6.5–82.8)	1082	424	39.2 (31.8–47.0)
40–52	330	149	45.2 (15.0–78.2)	287	90	31.4 (2.8–79.1)	465	185	39.8 (6.5–82.8)	1082	424	39.2 (31.8–47.0)
40-01*	330	149	45.2 (15.0–78.2)	287	90	31.4 (2.8–79.1)	465	185	39.8 (6.5–82.8)	1082	424	39.2 (31.8–47.0)

AE, adverse event; CI, confidence interval (extended Clopper–Pearson exact CI for clustered data); ISO, International Organization for Standardization; LL, lower limit; *N*, number of participants vaccinated with GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4) in the specified ISO weeks; *n*, number of participants vaccinated with GSK's IIV4 in the specified ISO weeks reporting at least one AE; UL, upper limit; % = (*n*/*N*) x 100

* first ISO week of 2020

Table S4 Cumulative percentages of participants reporting any AEs within 7 days post vaccination with dose 2 (Safety Set)

Spain			
ISO week	<i>N</i>	<i>n</i>	% (95% CI: LL-UL)
40–48	4	1	25.0 (0.6–80.6)
40–49	24	4	16.7 (4.7–37.4)
40–50	46	6	13.0 (4.9–26.3)
40–51	76	6	7.9 (1.0–25.3)
40–52	101	9	8.9 (2.2–22.2)
40–01*	115	9	7.8 (1.6–21.2)

AE, adverse event; CI, confidence interval (extended Clopper–Pearson exact CI for clustered data); ISO, International Organization for Standardization; LL, lower limit; *N*, number of participants vaccinated with GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4) in the specified ISO weeks; *n*, number of participants vaccinated with GSK's IIV4 in the specified ISO weeks reporting at least one AE; UL, upper limit; % = (*n*/*N*) x 100

* first ISO week of 2020

Table S5 Cumulative percentages of participants reporting any AEs post vaccination with dose 1 by age category (Safety Set)

ISO week	Belgium			Germany			Spain			Total		
	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)
6 months to 17 years												
40–44	0			0			56	26	46.4 (33.0–60.3)	56	26	46.4 (33.0–60.3)
40–45	0			0			141	55	39.0 (30.9–47.6)	141	55	39.0 (30.9–47.6)
40–46	0			0			253	95	37.6 (25.3–51.2)	253	95	37.6 (25.3–51.2)
40–47	0			0			308	118	38.3 (19.7–59.9)	308	118	38.3 (19.7–59.9)
40–48	0			0			323	123	38.1 (22.6–55.5)	323	123	38.1 (22.6–55.5)
40–49	0			0			331	126	38.1 (23.0–55.1)	331	126	38.1 (23.0–55.1)
40–50	0			0			331	126	38.1 (23.0–55.1)	331	126	38.1 (23.0–55.1)
40–51	0			0			331	126	38.1 (23.0–55.1)	331	126	38.1 (23.0–55.1)
40–52	0			0			331	126	38.1 (23.0–55.1)	331	126	38.1 (23.0–55.1)
40–01*	0			0			331	126	38.1 (23.0–55.1)	331	126	38.1 (23.0–55.1)
18–65 years												
40–40	0			25	11	44.0 (0.0–100.0)	0			25	11	44.0 (0.0–100.0)
40–41	0			94	44	46.8 (2.4–96.2)	0			94	44	46.8 (2.4–96.2)
40–42	112	61	54.5 (44.8–63.9)	115	52	45.2 (1.0–97.8)	0			227	113	49.8 (23.8–75.8)
40–43	128	68	53.1 (44.1–62.0)	117	53	45.3 (1.1–97.6)	0			245	121	49.4 (25.5–73.5)
40–44	130	69	53.1 (44.1–61.9)	117	53	45.3 (1.1–97.6)	0			247	122	49.4 (29.2–69.7)
40–45	132	70	53.0 (44.2–61.8)	117	53	45.3 (1.1–97.6)	0			249	123	49.4 (31.2–67.7)
40–46	136	72	52.9 (44.2–61.6)	117	53	45.3 (1.1–97.6)	74	31	41.9 (30.5–53.9)	327	156	47.7 (33.7–62.0)
40–47	137	72	52.6 (43.9–61.1)	117	53	45.3 (1.1–97.6)	130	58	44.6 (35.9–53.6)	384	183	47.7 (35.8–59.8)
40–48	139	72	51.8 (42.5–61.0)	117	53	45.3 (1.1–97.6)	134	59	44.0 (35.5–52.9)	390	184	47.2 (35.2–59.4)
40–49	139	72	51.8 (42.5–61.0)	117	53	45.3 (1.1–97.6)	134	59	44.0 (35.5–52.9)	390	184	47.2 (35.2–59.4)
40–50	139	72	51.8 (42.5–61.0)	117	53	45.3 (1.1–97.6)	134	59	44.0 (35.5–52.9)	390	184	47.2 (35.2–59.4)
40–51	139	72	51.8 (42.5–61.0)	117	53	45.3 (1.1–97.6)	134	59	44.0 (35.5–52.9)	390	184	47.2 (35.2–59.4)

40–52	139	72	51.8 (42.5–61.0)	117	53	45.3 (1.1–97.6)	134	59	44.0 (35.5–52.9)	390	184	47.2 (35.2–59.4)
40–01*	139	72	51.8 (42.5–61.0)	117	53	45.3 (1.1–97.6)	134	59	44.0 (35.5–52.9)	390	184	47.2 (35.2–59.4)
>65 years												
40–40	0			40	2	5.0 (0.0–44.1)	0			40	2	5.0 (0.0–44.1)
40–41	0			121	24	19.8 (0.0–89.6)	0			121	24	19.8 (0.0–89.6)
40–42	1	0	0.0 (0.0–97.5)	156	34	21.8 (0.1–84.8)	0			157	34	21.7 (1.3–67.4)
40–43	3	0	0.0 (0.0–70.8)	170	37	21.8 (0.2–80.8)	0			173	37	21.4 (3.2–56.1)
40–44	12	8	66.7 (0.0–100.0)	170	37	21.8 (0.2–80.8)	0			182	45	24.7 (5.6–56.1)
40–45	88	39	44.3 (4.8–91.0)	170	37	21.8 (0.2–80.8)	0			258	76	29.5 (12.4–52.2)
40–46	149	62	41.6 (9.0–81.1)	170	37	21.8 (0.2–80.8)	0			319	99	31.0 (15.7–50.2)
40–47	180	72	40.0 (10.5–76.4)	170	37	21.8 (0.2–80.8)	0			350	109	31.1 (17.0–48.5)
40–48	189	77	40.7 (12.7–74.3)	170	37	21.8 (0.2–80.8)	0			359	114	31.8 (17.6–49.0)
40–49	191	77	40.3 (12.2–74.3)	170	37	21.8 (0.2–80.8)	0			361	114	31.6 (17.6–48.6)
40–50	191	77	40.3 (12.2–74.3)	170	37	21.8 (0.2–80.8)	0			361	114	31.6 (17.6–48.6)
40–51	191	77	40.3 (12.2–74.3)	170	37	21.8 (0.2–80.8)	0			361	114	31.6 (17.6–48.6)
40–52	191	77	40.3 (12.2–74.3)	170	37	21.8 (0.2–80.8)	0			361	114	31.6 (17.6–48.6)
40–01*	191	77	40.3 (12.2–74.3)	170	37	21.8 (0.2–80.8)	0			361	114	31.6 (17.6–48.6)

AE, adverse event; CI, confidence interval (extended Clopper–Pearson exact CI for clustered data); ISO, International Organization for Standardization; LL, lower limit; *N*, number of participants vaccinated with GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4) in the specified ISO weeks; *n*, number of participants vaccinated with GSK's IIV4 in the specified ISO weeks reporting at least one AE; UL, upper limit; % = (*n*/*N*) x 100

* first ISO week of 2020

Table S6 Cumulative percentages of participants reporting any AEs within 7 days post vaccination with dose 1 by risk status^a (Safety Set)

ISO week	Belgium			Germany			Spain			Total		
	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)
At risk												
40–40	0			23	2	8.7 (0.0–93.4)	0			23	2	8.7 (0.0–93.4)
40–41	0			108	31	28.7 (0.0–96.4)	0			108	31	28.7 (0.0–96.4)
40–42	7	4	57.1 (18.4–90.1)	153	45	29.4 (0.4–89.8)	0			160	49	30.6 (4.4–72.7)
40–43	11	5	45.5 (0.1–99.8)	168	48	28.6 (0.8–84.6)	0			179	53	29.6 (8.5–60.3)
40–44	22	14	63.6 (0.0–100.0)	168	48	28.6 (0.8–84.6)	17	8	47.1 (23.0–72.2)	207	70	33.8 (16.2–55.5)
40–45	100	46	46.0 (7.4–88.9)	168	48	28.6 (0.8–84.6)	58	23	39.7 (27.1–53.4)	326	117	35.9 (23.4–50.0)
40–46	165	71	43.0 (10.9–80.4)	168	48	28.6 (0.8–84.6)	172	66	38.4 (2.6–89.3)	505	185	36.6 (28.3–45.6)
40–47	197	81	41.1 (11.4–76.7)	168	48	28.6 (0.8–84.6)	238	99	41.6 (0.3–98.5)	603	228	37.8 (29.4–46.8)
40–48	208	86	41.4 (13.0–74.8)	168	48	28.6 (0.8–84.6)	248	101	40.7 (0.4–97.9)	624	235	37.7 (29.7–46.1)
40–49	210	86	41.0 (12.5–74.8)	168	48	28.6 (0.8–84.6)	254	103	40.6 (0.3–98.0)	632	237	37.5 (29.6–46.0)
40–50	210	86	41.0 (12.5–74.8)	168	48	28.6 (0.8–84.6)	254	103	40.6 (0.3–98.0)	632	237	37.5 (29.6–46.0)
40–51	210	86	41.0 (12.5–74.8)	168	48	28.6 (0.8–84.6)	254	103	40.6 (0.3–98.0)	632	237	37.5 (29.6–46.0)
40–52	210	86	41.0 (12.5–74.8)	168	48	28.6 (0.8–84.6)	254	103	40.6 (0.3–98.0)	632	237	37.5 (29.6–46.0)
40–01*	210	86	41.0 (12.5–74.8)	168	48	28.6 (0.8–84.6)	254	103	40.6 (0.3–98.0)	632	237	37.5 (29.6–46.0)
Not at risk												
40–40	0			42	11	26.2 (0.0–94.2)	0			42	11	26.2 (0.0–94.2)
40–41	0			107	37	34.6 (5.1–77.8)	0			107	37	34.6 (5.1–77.8)
40–42	106	57	53.8 (43.8–63.5)	118	41	34.8 (2.9–84.2)	0			224	98	43.8 (18.9–71.1)
40–43	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	0			239	105	43.9 (20.5–69.5)
40–44	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	39	18	46.2 (30.1–62.8)	278	123	44.2 (27.0–62.6)
40–45	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	83	32	38.6 (28.1–49.9)	322	137	42.6 (26.5–59.9)
40–46	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	155	60	38.7 (31.0–46.9)	394	165	41.9 (29.4–55.2)
40–47	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	200	77	38.5 (31.7–45.6)	439	182	41.5 (30.0–53.6)

40–48	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	209	81	38.8 (32.1–45.7)	448	186	41.5 (30.3–53.4)
40–49	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	211	82	38.9 (32.3–45.8)	450	187	41.6 (30.5–53.3)
40–50	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	211	82	38.9 (32.3–45.8)	450	187	41.6 (30.5–53.3)
40–51	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	211	82	38.9 (32.3–45.8)	450	187	41.6 (30.5–53.3)
40–52	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	211	82	38.9 (32.3–45.8)	450	187	41.6 (30.5–53.3)
40–01*	120	63	52.5 (43.2–61.7)	119	42	35.3 (2.8–85.2)	211	82	38.9 (32.3–45.8)	450	187	41.6 (30.5–53.3)

AE, adverse event; CI, confidence interval (extended Clopper–Pearson exact CI for clustered data); ISO, International Organization for Standardization; LL, lower limit; *N*, number of participants vaccinated with GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4) in the specified ISO weeks; *n*, number of participants vaccinated with GSK's IIV4 in the specified ISO weeks reporting at least one AE; UL, upper limit; % = (*n*/*N*) x 100

^a risk status for influenza-associated morbidity and mortality as assessed by the healthcare provider based on their judgment and experience

* first ISO week of 2020

Table S7 Cumulative percentages of participants reporting any AEs within 7 days post vaccination with dose 2 by risk status^a (Safety Set)

ISO week	Spain		
	<i>N</i>	<i>n</i>	% (95% CI: LL–UL)
At risk			
40–48	1	0	0.0 (0.0–97.5)
40–49	9	1	11.1 (0.3–48.3)
40–50	16	2	12.5 (1.6–38.4)
40–51	27	2	7.4 (0.9–24.3)
40–52	43	5	11.6 (3.9–25.1)
40–01*	49	5	10.2 (3.4–22.2)
Not at risk			
40–48	3	1	33.3 (0.8–90.6)
40–49	15	3	20.0 (4.3–48.1)
40–50	30	4	13.3 (3.8–30.7)
40–51	49	4	8.2 (0.1–40.5)
40–52	58	4	6.9 (0.3–29.2)
40–01*	66	4	6.1 (0.5–22.7)

AE, adverse event; CI, confidence interval (extended Clopper–Pearson exact CI for clustered data); ISO, International Organization for Standardization; LL, lower limit; *N*, number of participants vaccinated with GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4) in the specified ISO weeks; *n*, number of participants vaccinated with GSK's IIV4 in the specified ISO weeks reporting at least one AE; UL, upper limit; % = (*n*/*N*) x 100

^a risk status for influenza-associated morbidity and mortality as assessed by the healthcare provider based on their judgment and experience

* first ISO week of 2020

Table S8 Participants reporting any AEs within 7 days post vaccination with dose 1 by risk status (Safety Set)

MedDRA Primary System Organ Class (Code)	Belgium				Germany				Spain				Total			
	<i>N</i> = 210 at risk				<i>N</i> = 168 at risk				<i>N</i> = 254 at risk				<i>N</i> = 632 at risk			
	<i>N</i> = 120 not at risk				<i>N</i> = 119 not at risk				<i>N</i> = 211 not at risk				<i>N</i> = 450 not at risk			
	95% CI				95% CI				95% CI				95% CI			
	<i>n</i>	%	LL	UL	<i>n</i>	%	LL	UL	<i>n</i>	%	LL	UL	<i>n</i>	%	LL	UL
Any																
At risk	86	41.0	12.5	74.8	48	28.6	0.8	84.6	103	40.6	0.3	98.0	237	37.5	29.6	46.0
Not at risk	63	52.5	43.2	61.7	42	35.3	2.8	85.2	82	38.9	32.3	45.8	187	41.6	30.5	53.3
Any ear and labyrinth disorders (10013993)																
At risk	1	0.5	0.0	2.6	0	0.0	0.0	2.2	0	0.0	0.0	1.4	1	0.2	0.0	0.9
Not at risk	0	0.0	0.0	3.0	0	0.0	0.0	3.1	0	0.0	0.0	1.7	0	0.0	0.0	0.8
Any eye disorders (10015919)																
At risk	1	0.5	0.0	15.9	0	0.0	0.0	2.2	5	2.0	0.0	72.2	6	1.0	0.1	3.6
Not at risk	0	0.0	0.0	3.0	2	1.7	0.0	14.9	1	0.5	0.0	7.4	3	0.7	0.0	3.0
Any gastrointestinal disorders (10017947)																
At risk	11	5.2	0.8	16.8	6	3.6	0.4	13.2	20	7.9	0.0	93.5	37	5.9	3.1	10.0
Not at risk	4	3.3	0.9	8.3	2	1.7	0.1	8.6	14	6.6	3.7	10.9	20	4.4	1.9	8.6
Any general disorders and administration site conditions (10018065)																
At risk	60	28.6	5.9	64.2	38	22.6	0.8	73.6	84	33.1	0.0	97.9	182	28.8	21.1	37.6
Not at risk	59	49.2	39.9	58.5	37	31.1	3.3	77.1	68	32.2	13.7	56.1	164	36.4	24.2	50.2
Any immune system disorders (10021428)																
At risk	0	0.0	0.0	1.7	0	0.0	0.0	2.2	2	0.8	0.0	73.1	2	0.3	0.0	2.1
Not at risk	0	0.0	0.0	3.0	2	1.7	0.1	8.6	1	0.5	0.0	7.4	3	0.7	0.1	2.1

Any infections and infestations (10021881)																
At risk	0	0.0	0.0	1.7	3	1.8	0.0	11.9	4	1.6	0.4	4.0	7	1.1	0.3	2.9
Not at risk	0	0.0	0.0	3.0	3	2.5	0.0	51.1	0	0.0	0.0	1.7	3	0.7	0.0	6.9
Any metabolism and nutrition disorders (10027433)																
At risk	3	1.4	0.0	18.2	0	0.0	0.0	2.2	10	3.9	1.9	7.1	13	2.1	0.6	5.1
Not at risk	1	0.8	0.0	4.6	1	0.8	0.0	7.7	4	1.9	0.0	26.9	6	1.3	0.4	3.1
Any musculoskeletal and connective tissue disorders (10028395)																
At risk	21	10.0	1.6	29.1	11	6.6	3.3	11.4	17	6.7	0.0	97.7	49	7.8	4.7	11.8
Not at risk	16	13.3	7.8	20.8	11	9.2	0.4	37.4	8	3.8	0.0	72.9	35	7.8	2.2	18.7
Any nervous system disorders (10029205)																
At risk	19	9.1	4.2	16.5	10	6.0	0.7	20.1	26	10.2	0.0	90.7	55	8.7	5.9	12.3
Not at risk	12	10.0	5.3	16.8	7	5.9	0.6	20.9	17	8.1	0.1	42.4	36	8.0	5.7	10.9
Any psychiatric disorders (10037175)																
At risk	0	0.0	0.0	1.7	2	1.2	0.0	8.1	5	2.0	0.0	11.8	7	1.1	0.3	2.8
Not at risk	0	0.0	0.0	3.0	1	0.8	0.0	7.7	6	2.8	1.1	6.1	7	1.6	0.3	4.8
Any respiratory, thoracic and mediastinal disorders (10038738)																
At risk	19	9.1	0.4	37.2	10	6.0	1.5	15.2	21	8.3	2.1	20.8	50	7.9	5.6	10.8
Not at risk	2	1.7	0.2	5.9	7	5.9	0.0	74.1	12	5.7	0.3	24.8	21	4.7	1.3	11.7
Any skin and subcutaneous tissue disorders (10040785)																
At risk	8	3.8	1.7	7.4	3	1.8	0.0	11.9	8	3.2	0.0	95.8	19	3.0	1.3	5.8
Not at risk	1	0.8	0.0	4.6	3	2.5	0.3	9.0	9	4.3	0.2	19.7	13	2.9	1.2	5.8

AE, adverse event; CI, confidence interval (extended Clopper–Pearson exact CI for clustered data); MedDRA, Medical Dictionary for Regulatory Activities; LL, lower limit; *N*, total number of participants; *n*, number of participants vaccinated with GSK's IIV4 reporting at least one AE; UL, upper limit; % = (*n*/*N*) x 100

Table S9 Participants reporting any AEs within 7 days post vaccination with dose 2 by risk status (Safety Set)

MedDRA Primary System Organ Class (Code)	Spain	
	<i>n</i>	<i>% (95% CI: LL–UL)</i>
	<i>N</i> = 49 at risk	
	<i>N</i> = 66 not at risk	
Any		
At risk	5	10.2 (3.4–22.2)
Not at risk	4	6.1 (0.5–22.7)
Any general disorders and administration site conditions (10018065)		
At risk	2	4.1 (0.5–14.0)
Not at risk	3	4.6 (0.4–17.3)
Any respiratory, thoracic, and mediastinal disorders (10038738)		
At risk	3	6.1 (1.3–16.9)
Not at risk	1	1.5 (0.0–8.2)
Any gastrointestinal disorders (10017947)		
At risk	1	2.0 (0.1–10.9)
Not at risk	1	1.5 (0.0–8.2)
Any infections and infestations (10021881)		
At risk	1	2.0 (0.1–10.9)
Not at risk	1	1.5 (0.0–8.2)

AE, adverse event; CI, confidence interval (extended Clopper–Pearson exact CI for clustered data); MedDRA, Medical Dictionary for Regulatory Activities; LL, lower limit; *N*, number of participants vaccinated with GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4); *n*, number of participants vaccinated with GSK's IIV4 reporting at least one AE; UL, upper limit; % = (*n*/*N*) x 100

Table S10 Cumulative percentages of participants in the Solicited Safety Set reporting AEs (in italics) and/or other AEs post vaccination with dose 1

MedDRA Primary System Organ Class (Code) Preferred Term (Code)	Belgium <i>N</i> = 315				Germany <i>N</i> = 279				Spain <i>N</i> = 455				Total <i>N</i> = 1,049			
	<i>n</i>	%	95% CI		<i>n</i>	%	95% CI		<i>n</i>	%	95% CI		<i>n</i>	%	95% CI	
			LL	UL			LL	UL			LL	UL			LL	UL
Any	149	47.3	9.8	87.4	90	32.3	2.2	83.1	185	40.7	2.26	92.4	424	40.4	31.6	49.8
Ear and labyrinth disorders (10013993)																
Any	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Ear pain (10014020)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Eye disorders (10015919)																
Any	1	0.3	0.0	10.1	2	0.7	0.0	13.7	6	1.3	0.0	63.9	9	0.9	0.2	2.4
<i>Eye allergy (10015907)</i>	1	0.3	0.0	10.1	2	0.7	0.0	13.7	5	1.1	0.0	42.8	8	0.8	0.2	1.9
Ocular hyperaemia (10030041)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	46.8	1	0.1	0.0	0.7
Gastrointestinal disorders (10017947)																
Any	15	4.8	1.2	12.1	8	2.9	0.1	15.4	34	7.5	0.0	73.4	57	5.4	3.3	8.4
<i>Diarrhoea (10012735)</i>	5	1.6	0.0	17.2	4	1.4	0.0	7.9	16	3.5	0.4	12.2	25	2.4	1.2	4.2
<i>Lip swelling (10024570)</i>	0	0.0	0.0	1.2	0	0.0	0.0	1.3	0	0.0	0.0	0.8	0	0.0	0.0	0.4
<i>Nausea (10028813)</i>	7	2.2	0.9	4.5	2	0.7	0.0	13.7	12	2.6	0.0	87.5	21	2.0	0.8	4.2
<i>Swollen tongue (10042727)</i>	0	0.0	0.0	1.2	0	0.0	0.0	1.3	0	0.0	0.0	0.8	0	0.0	0.0	0.4
<i>Vomiting (10047700)</i>	4	1.3	0.0	10.0	3	1.1	0.0	14.2	5	1.1	0.0	6.2	12	1.1	0.6	2.0
Abdominal pain upper (10000087)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	2	0.4	0.0	9.2	3	0.3	0.1	0.8
Constipation (10010774)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Dry mouth (10013781)	1	0.3	0.0	3.7	1	0.4	0.0	5.0	1	0.2	0.0	46.8	3	0.3	0.1	0.9
Flatulence (10016766)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	13.4	1	0.1	0.0	0.5
Frequent bowel movements (10017367)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	46.8	1	0.1	0.0	0.7
Lip dry (10024552)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	46.8	1	0.1	0.0	0.7
Stomatitis (10042128)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	13.4	1	0.1	0.0	0.5
General disorders and administration site conditions (10018065)																

Any	119	37.8	1.7	91.2	75	26.9	2.9	70.5	152	33.4	0.3	95.0	346	33.0	23.7	43.3
<i>Chills (10008531)</i>	3	1.0	0.2	2.8	16	5.7	2.9	10.1	19	4.2	0.0	85.4	38	3.6	1.7	6.7
<i>Fatigue (10016256)</i>	26	8.3	0.9	27.9	17	6.1	0.3	25.2	39	8.6	0.0	62.5	82	7.8	5.5	10.8
<i>Injection site erythema (10022061)</i>	8	2.5	0.2	10.2	18	6.5	1.1	19.4	31	6.8	2.5	14.3	57	5.4	3.4	8.3
<i>Injection site pain (10022086)</i>	96	30.5	0.5	89.9	57	20.4	2.1	59.0	119	26.2	0.0	93.9	272	25.9	17.2	36.4
<i>Injection site swelling (10053425)</i>	14	4.4	1.8	8.9	16	5.7	0.1	28.3	37	8.1	0.7	28.9	67	6.4	4.3	9.1
<i>Fever (10037660)</i>	5	1.6	0.0	9.7	3	1.1	0.0	6.8	22	4.8	1.1	13.3	30	2.9	1.3	5.5
Asthenia (10003549)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	46.8	1	0.1	0.0	0.7
Discomfort (10013082)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	2	0.4	0.0	25.1	2	0.2	0.0	1.0
Feeling cold (10016326)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Influenza-like illness (10022004)	4	1.3	0.0	10.0	0	0.0	0.0	1.3	0	0.0	0.0	0.8	4	0.4	0.0	2.0
Injection site bruising (10022052)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	2	0.4	0.0	71.8	2	0.2	0.0	1.4
Injection site discolouration (10051572)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Injection site discomfort (10054266)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	46.8	1	0.1	0.0	0.7
injection site haematoma (10022066)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	13.4	1	0.1	0.0	0.5
Injection site induration (10022075)	2	0.6	0.1	2.3	0	0.0	0.0	1.3	0	0.0	0.0	0.8	2	0.2	0.0	0.8
Injection site movement impairment (10056250)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Injection site pruritus (10022093)	2	0.6	0.0	7.4	0	0.0	0.0	1.3	0	0.0	0.0	0.8	2	0.2	0.0	1.4
Injection site warmth (10022112)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	13.4	1	0.1	0.0	0.5
Peripheral swelling (10048959)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	2	0.4	0.0	9.2	2	0.2	0.0	0.7
Immune system disorders (10021428)																
Any	0	0.0	0.0	1.2	2	0.7	0.1	2.7	3	0.7	0.0	39.6	5	0.5	0.1	1.2
<i>Hypersensitivity (10020751)</i>	0	0.0	0.0	1.2	2	0.7	0.1	2.7	3	0.7	0.0	39.6	5	0.5	0.1	1.2
Infections and infestations (10021881)																
Any	0	0.0	0.0	1.2	6	2.2	0.0	26.8	4	0.9	0.0	17.6	10	1.0	0.1	3.4
Influenza (10022000)	0	0.0	0.0	1.2	3	1.1	0.0	14.2	0	0.0	0.0	0.8	3	0.3	0.0	2.2
Nasopharyngitis (10028810)	0	0.0	0.0	1.2	3	1.1	0.0	14.2	2	0.4	0.0	71.8	5	0.5	0.0	2.1

Pharyngitis (10034835)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	13.4	1	0.1	0.0	0.5
Upper respiratory tract infection (10046306)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	13.4	1	0.1	0.0	0.5
Investigations (10022891)																
Any	0	0.0	0.0	1.2	1	0.4	0.0	5.0	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Heart rate increased (10019303)	0	0.0	0.0	1.2	1	0.4	0.0	5.0	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Metabolism and nutrition disorders (10027433)																
Any	4	1.3	0.0	10.0	1	0.4	0.0	7.1	14	3.1	0.9	7.4	19	1.8	0.7	3.7
<i>Decreased appetite (10061428)</i>	4	1.3	0.0	10.0	1	0.4	0.0	7.1	14	3.1	0.9	7.4	19	1.8	0.7	3.7
Musculoskeletal and connective tissue disorders (10028395)																
Any	37	11.8	2.4	31.2	22	7.9	2.7	17.3	25	5.5	0.0	98.0	84	8.0	4.1	13.9
<i>Arthralgia (10003239)</i>	10	3.2	0.1	17.7	10	3.6	0.0	28.1	17	3.7	0.0	93.2	37	3.5	1.5	6.9
<i>Myalgia (10028411)</i>	31	9.8	2.7	23.5	14	5.0	0.1	29.2	12	2.6	0.0	87.5	57	5.4	2.1	11.2
Muscle twitching (10028347)	0	0.0	0.0	1.2	1	0.4	0.0	5.0	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Muscular weakness (10028372)	1	0.3	0.0	6.2	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Musculoskeletal stiffness (10052904)	1	0.3	0.0	6.2	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Nervous system disorders (10029205)																
Any	31	9.8	4.1	19.2	17	6.1	0.7	21.1	43	9.5	0.0	88.0	91	8.7	6.0	12.0
<i>Dizziness (10013573)</i>	10	3.2	1.5	5.8	6	2.2	0.0	15.7	9	2.0	0.0	52.0	25	2.4	1.4	3.9
<i>Headache (10019211)</i>	23	7.3	0.8	25.0	14	5.0	0.5	18.2	37	8.1	0.0	82.6	74	7.1	4.6	10.3
Dysgeusia (10013911)	0	0.0	0.0	1.2	1	0.4	0.0	5.0	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Hypersomnia (10020765)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	46.8	1	0.1	0.0	0.7
Poor quality sleep (10062519)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Psychomotor hyperactivity (10037211)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	13.4	1	0.1	0.0	0.5
Sensory disturbance (10040026)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Somnolence (10041349)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	13.4	1	0.1	0.0	0.5
Psychiatric disorders (10037175)																
Any	0	0.0	0.0	1.2	3	1.1	0.1	4.5	11	2.4	0.4	7.5	14	1.3	0.4	3.1
<i>Irritability (10022998)</i>	0	0.0	0.0	1.2	2	0.7	0.1	2.7	11	2.4	0.4	7.5	13	1.2	0.3	3.2

Restlessness (10038743)	0	0.0	0.0	1.2	1	0.4	0.0	5.0	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Respiratory, thoracic and mediastinal disorders (10038738)																
Any	21	6.7	0.1	33.8	17	6.1	0.0	38.9	33	7.3	1.5	19.7	71	6.8	4.3	10.1
<i>Rhinorrhoea (10039101)</i>	18	5.7	0.0	36.4	11	3.9	0.1	23.0	30	6.6	1.2	19.1	59	5.6	3.4	8.6
Cough (10011224)	2	0.6	0.0	5.9	4	1.4	0.0	18.0	4	0.9	0.0	17.6	10	1.0	0.4	2.1
Dysphonia (10013952)	1	0.3	0.0	3.7	1	0.4	0.0	5.0	0	0.0	0.0	0.8	2	0.2	0.0	0.8
Dyspnoea (10013968)	1	0.3	0.0	10.1	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.8
Epistaxis (10015090)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Increased upper airway secretion (10062717)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	13.4	1	0.1	0.0	0.5
Oropharyngeal pain (10068319)	1	0.3	0.0	6.2	5	1.8	0.0	13.8	1	0.2	0.0	13.4	7	0.7	0.1	2.3
Sneezing (10041232)	0	0.0	0.0	1.2	1	0.4	0.0	5.0	1	0.2	0.0	13.4	2	0.2	0.0	0.7
Tonsillar inflammation (10065169)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	1	0.2	0.0	46.8	1	0.1	0.0	0.7
Skin and subcutaneous tissue disorders (10040785)																
Any	9	2.9	0.1	14.6	6	2.2	0.2	9.0	17	3.7	0.0	68.0	32	3.1	1.8	4.9
<i>Pruritus (10037087)</i>	7	2.2	0.0	17.6	4	1.4	0.2	5.4	12	2.6	0.0	45.0	23	2.2	1.2	3.7
<i>Rash (10037844)</i>	3	1.0	0.2	2.8	0	0.0	0.0	1.3	3	0.7	0.0	39.6	6	0.6	0.2	1.3
<i>Swelling face (10042682)</i>	0	0.0	0.0	1.2	0	0.0	0.0	1.3	0	0.0	0.0	0.8	0	0.0	0.0	0.4
Erythema (10015150)	0	0.0	0.0	1.2	0	0.0	0.0	1.3	2	0.4	0.0	9.2	2	0.2	0.0	0.7
Night sweats (10029410)	0	0.0	0.0	1.2	1	0.4	0.0	5.0	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Rash macular (10037867)	0	0.0	0.0	1.2	1	0.4	0.0	5.0	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Vascular disorders (10047065)																
Any	2	0.6	0.1	2.3	0	0.0	0.0	1.3	0	0.0	0.0	0.8	2	0.2	0.0	0.8
Hot flush (10060800)	1	0.3	0.0	6.2	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7
Hypertension (10020772)	1	0.3	0.0	3.7	0	0.0	0.0	1.3	0	0.0	0.0	0.8	1	0.1	0.0	0.7

Bold values represent the MedDRA Primary System Organ Class. Terms in italics represent Preferred Terms which correspond to the predefined AEs

AEs, adverse events; AEIs, adverse events of interest; CI, confidence interval (extended Clopper–Pearson exact CI for clustered data); MedDRA, Medical Dictionary for Regulatory Activities; LL, lower limit; *N*, number of participants vaccinated with GSK's inactivated quadrivalent seasonal influenza vaccine (IIV4); *n*, number of participants vaccinated with GSK's IIV4 reporting at least one AE; UL, upper limit; % = (n/N) x 100